The ABI2 Knouckout Jurkat Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted polyclonal population targeting the ABI2 locus in Jurkat T lymphocyte leukemia cells. This loss-of-function model avoids the limitations of transient siRNA or chemical inhibitors, offering a stable system to dissect ABI2-dependent pathways in a relevant human lymphoid background.
The Jurkat cell line, derived from a patient with acute T cell leukemia, serves as a standard model for T cell receptor (TCR) signaling, activation, and apoptosis. Its capacity to form functional immune synapses and its well-mapped phospho-signaling network make it ideal for studying actin-cytoskeleton coupling and leukemogenic processes.
ABI2 is an adaptor that bridges Abl and Src family kinases to the WAVE regulatory complex. Upon TCR ligation, ZAP70 and SLP-76 activate Vav1, which stimulates Rac1. Rac1-GTP recruits the WAVE2 complex??ABI2, CYFIP1, NCKAP1, and HSPC300??to the membrane, where it activates Arp2/3, driving branched actin polymerization. ABI2 interacts with profilin and F-actin, linking kinase cascades to lamellipodia formation, cell adhesion, and immune synapse assembly. Disrupting ABI2 uncouples TCR signals from actin remodeling, enabling precise investigation of this mechanical checkpoint.
In Jurkat cells, ABI2 knockout impairs TCR-induced actin reorganization, defective WAVE2 complex recruitment, and reduced Arp2/3-mediated branching, leading to compromised cell spreading, adhesion, and migration. This phenotype directly disrupts immune synapse maturation and downstream signaling activation, making the model valuable for studying T cell activation thresholds and the interplay between cytoskeletal dynamics and signal transduction. Moreover, as a leukemic line, these cells offer a platform to examine how oncogenic signals exploit actin regulatory programs for metastasis.
Applications include Western blot and RT-qPCR for ABI2 expression, flow cytometry for CD69/CD25 and phospho-ZAP70/ERK, actin polymerization assays (phalloidin staining), and confocal immune synapse imaging. Migration and adhesion assays extend utility to drug screening for immunomodulatory or anti-metastatic compounds. For further assistance, contact Ascent Research.
